Kemp Dolliver

Join leading investor and BD voices as they delve into the real risk–reward equation – from funding strategy and scaling RLTs to forging partnerships that accelerate patient access and ROI. Bring your questions and gain true insights into what it really takes to drive growth while mitigating risk in this rapidly evolving space.

• Evaluating economic challenges and opportunities in scaling RLTs from preclinical discovery to commercial launch
• Identifying strategies for securing ongoing investment despite supply chain and regulatory constraints
• Exploring collaborative models with manufacturers, regulators, and advocacy groups to accelerate patient access and return on investment

• Analyzing the interplay between regulatory uncertainty, clinical complexity, and investor risk perception
• Prioritizing scientific strategies that improve translational success and attract sustainable funding
• Demonstrating the value proposition of next-generation TRPs to stakeholders, including patient advocates, payers, and industry partners